Answer
MMRVAXPRO can be injected intramuscularly or subcutaneously, but patients with thrombocytopenia or any coagulation disorder should receive it subcutaneously, and it must not be injected intravascularly.
Sources for this answer
- MMRVAXPROMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.2 Posology and method of administration · Version 23Document updated
Sources checked